{"product_id":"schizophrenia-isbn-9781405176972","title":"Schizophrenia","description":"Schizophrenia is one of the most complex and disabling diseases to affect mankind.   Relatively little is known about its nature and its origins, and available treatments are inadequate for most patients. As a result, there are inevitable controversies about what causes it, how to diagnose it, and how best to treat it.   However, in the past decade, there has been an explosion of new research, with dramatic discoveries involving genetic etiology and epidemiological risk factors.  There has also been a catalog of new drugs coming to market, and controversy about the relative advantages and disadvantages of newer compared with older therapies.   In addition, developing technologies in genomics, molecular biology and neuroimaging provide streams of new information. \u003cp\u003eThis book represents a definitive, essential, and up-to-date reference text on schizophrenia. It extensively and critically digests and clarifies recent advances and places them within a clinical context.  The Editors (one American and one British), highly respected clinical psychiatrists and researchers and acknowledged experts on schizophrenia, have again assembled an outstanding group of contributors from the USA, UK, Europe and Australia, It will be of value to practising psychiatrists and to trainees, as well as to clinical and neuroscience researchers interested in keeping up with this field or coming into it.\u003c\/p\u003e \u003cp\u003eThe book consists of four sections:   descriptive aspects, biological aspects, physical treatments, and psychological and social aspects.   It reviews the theoretical controversies over symptomatology, classification and aetiology (particularly pertinent as DSM-V is being developed), the relationship of schizophrenia to the other psychoses, the significance of positive and negative symptoms and pre-morbid personality. It describes a variety of approaches to integrating the vast research data about schizophrenia, including neurodevelopmental, genetic, pharmacological, brain imaging and psychological findings. The biological treatment section reviews the comparative efficacy of various drugs, the management of drug-resistant patients and both neurological and metabolic complications. The final section looks at psychological therapies, social outcomes, and the economics of schizophrenia. \u003c\/p\u003e \u003cp\u003e\u003cb\u003eHighly Commended in the Psychiatry section of the 2012 BMA Book Awards.\u003c\/b\u003e\u003c\/p\u003e \u003cp\u003eContributors vii\u003c\/p\u003e \u003cp\u003eEditor’s Note xi\u003c\/p\u003e \u003cp\u003ePreface to the 3 Rd Edition xii\u003c\/p\u003e \u003cp\u003ePreface to the First Edition xiii\u003c\/p\u003e \u003cp\u003e\u003cb\u003ePart 1 Descriptive Aspects 1\u003c\/b\u003e\u003c\/p\u003e \u003cp\u003e1 Concept of schizophrenia: past present and future 3\u003cbr\u003e \u003ci\u003eNancy C. Andreasen\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003e2 The schizophrenia construct: symptomatic presentation 9\u003cbr\u003e \u003ci\u003eCelso Arango and William T. Carpenter\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003e3 Child and adolescent schizophrenia 24\u003cbr\u003e \u003ci\u003eChris Hollis and Judith Rapoport\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003e4 Late-onset schizophrenia 47\u003cbr\u003e \u003ci\u003eRobert Howard and Dilip Jeste\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003e5 The schizophrenia spectrum personality disorders 62\u003cbr\u003e \u003ci\u003eEran Chemerinski and Larry J. Siever\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003e6 The prodrome of schizophrenia 91\u003cbr\u003e \u003ci\u003eJean Addington and Shôn W. Lewis\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003e7 Course and outcome 104\u003cbr\u003e \u003ci\u003eWolfram an der Heiden and Heinz Häfner\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003e8 Neurocognitive impairments in schizophrenia: their character and role in symptom formation 142\u003cbr\u003e \u003ci\u003eTerry E. Goldberg Anthony David and James. M. Gold\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003e\u003cb\u003ePart 2 Biological Aspects 163\u003c\/b\u003e\u003c\/p\u003e \u003cp\u003e9 The secondary schizophrenias 165\u003cbr\u003e \u003ci\u003eThomas M. Hyde and Maria A. Ron\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003e10 Schizophrenia: the epidemiological horizon 185\u003cbr\u003e \u003ci\u003eAssen Jablensky James B. Kirkbride and Peter B. Jones\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003e11 Environmental risk factors for schizophrenia 226\u003cbr\u003e \u003ci\u003eJohn J. McGrath and Robin M. Murray\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003e12 Classical genetic studies of schizophrenia 245\u003cbr\u003e \u003ci\u003eBrien Riley and Kenneth S. Kendler\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003e13 Genetic associations in schizophrenia 269\u003cbr\u003e \u003ci\u003eMichael C. O’Donovan and Michael J. Owen\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003e14 Intermediate phenotypes in genetic studies of schizophrenia 289\u003cbr\u003e \u003ci\u003eMichael F. Egan and Tyrone D. Cannon\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003e15 Electrophysiology of schizophrenia 311\u003cbr\u003e \u003ci\u003eGeorg Winterer and Robert W. McCarley\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003e16 Structural brain imaging in schizophrenia and related populations 334\u003cbr\u003e \u003ci\u003eStephen M. Lawrie and Christos Pantelis\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003e17 Functional brain imaging in schizophrenia 353\u003cbr\u003e \u003ci\u003eAndreas Meyer-Lindenberg and Edward T. Bullmore\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003e18 Neuropathology of schizophrenia 372\u003cbr\u003e \u003ci\u003ePaul J. Harrison David A. Lewis and Joel E. Kleinman\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003e19 Neurodevelopmental origins of schizophrenia 393\u003cbr\u003e \u003ci\u003eDaniel R. Weinberger and Pat Levitt\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003e20 Dopamine and schizophrenia 413\u003cbr\u003e \u003ci\u003eAnissa Abi-Dargham and Anthony A. Grace\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003e21 Contributions of glutamate and GABA systems to the neurobiology and treatment of schizophrenia 433\u003cbr\u003e \u003ci\u003eJohn H. Krystal and Bita Moghaddam\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003e22 Animal models of schizophrenia 462\u003cbr\u003e \u003ci\u003eBarbara K. Lipska and Joseph A. Gogos\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003e\u003cb\u003ePart 3 Physical Treatments 483\u003c\/b\u003e\u003c\/p\u003e \u003cp\u003e23 Pharmacology and neuroscience of antipsychotic drugs 485\u003cbr\u003e \u003ci\u003eJohn L. Waddington Colm M.P. O’Tuathaigh and Gary J. Remington\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003e24 Principles of pharmacological treatment in schizophrenia 515\u003cbr\u003e \u003ci\u003eThomas R.E. Barnes and Stephen R. Marder\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003e25 Comparative efficacy and effectiveness in the drug treatment of schizophrenia 525\u003cbr\u003e \u003ci\u003eJohn R. Geddes T. Scott Stroup and Jeffrey A. Lieberman\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003e26 Approaches to treatment-resistant patients 540\u003cbr\u003e \u003ci\u003eStephan Leucht Christoph U. Correll and John M. Kane\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003e27 Neurological complications of antipsychotic drugs 561\u003cbr\u003e \u003ci\u003ePeter M. Haddad and Venkata S. Mattay\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003e28 Metabolic adverse effects associated with antipsychotic medications 577\u003cbr\u003e \u003ci\u003eJohn W. Newcomer and Stefan Leucht\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003e\u003cb\u003ePart 4 Psychosocial Aspects 599\u003c\/b\u003e\u003c\/p\u003e \u003cp\u003e29 Schizophrenia and psychosocial stresses 601\u003cbr\u003e \u003ci\u003ePaul E. Bebbington and Elizabeth Kuipers\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003e30 Mental health services for patients with schizophrenia 625\u003cbr\u003e \u003ci\u003eTom Burns and Bob Drake\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003e31 Societal outcomes in schizophrenia 644\u003cbr\u003e \u003ci\u003eIain Kooyman and Elizabeth Walsh\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003e32 Psychological treatment of psychosis 666\u003cbr\u003e \u003ci\u003eGillian Haddock and Will Spaulding\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003e33 Economics of the treatment of schizophrenia 687\u003cbr\u003e \u003ci\u003eNancy H. Covell Susan M. Essock and Linda K. Frisman\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003eIndex 701\u003c\/p\u003e \u003cp\u003eColour plates are found facing page 338\u003c\/p\u003e  \u003cp\u003e\"I thoroughly recommend this book as a well-integrated collection of thoughtful and up-to-date expositions on every aspect of schizophrenia, by some of the best scientists in the field. \" (\u003ci\u003ePsychological Medicine, 2012\u003c\/i\u003e)\u003cbr\u003e \u003cbr\u003e “It will be of valuable to practising psychiatrists and to trainees, as well as to the clinical and neuroscience researchers interested in keeping up with this field or coming into it.”  (\u003ci\u003eBuchtipps\u003c\/i\u003e,  September 2012)\u003c\/p\u003e \u003cp\u003e\"The contributing authors and editors constitute an international list of '\"who's who\" in contemporary schizophrenia research. Overall this book represents a highly systematic, comprehensive, scholarly, and critical appraisal of a core component of modern psychiatry and a major publice health challenge. It ably summarizes and evalutates efforts to better understand the nature, diagnosis, biology, psychology, sociology and clinical treatment of the group of largely \"nonaffective\" psychotic disorders currently considered within the nosological domain of schizophrenia. As such, it is an essential volume for students, researchers, clinicians, and administrators interested in improved understanding and care of persons diagnosed with psychotic disorders.\" (\u003ci\u003eJournal of Clinical Psychiatry, 2012\u003c\/i\u003e)\u003c\/p\u003e  \u003cb\u003eDaniel R. Weinberger\u003c\/b\u003e, Director: Genes, Cognition and Psychosis Program, National Institute of Mental  Health, National Institute of Health, Bethesda, USA\u003cbr\u003e \u003cbr\u003e   \u003cp\u003e\u003cb\u003ePaul J. Harrison\u003c\/b\u003e, University Department of Psychiatry, Warneford Hospital, Oxford, UK\u003c\/p\u003e  Schizophrenia is one of the most complex and disabling diseases to affect mankind.   Relatively little is known about its nature and its origins, and available treatments are inadequate for most patients. As a result, there are inevitable controversies about what causes it, how to diagnose it, and how best to treat it.   However, in the past decade, there has been an explosion of new research, with dramatic discoveries involving genetic etiology and epidemiological risk factors.  There has also been a catalog of new drugs coming to market, and controversy about the relative advantages and disadvantages of newer compared with older therapies.   In addition, developing technologies in genomics, molecular biology and neuroimaging provide streams of new information.  \u003cp\u003eThis book represents a definitive, essential, and up-to-date reference text on schizophrenia. It extensively and critically digests and clarifies recent advances and places them within a clinical context.  The Editors (one American and one British), highly respected clinical psychiatrists and researchers and acknowledged experts on schizophrenia, have again assembled an outstanding group of contributors from the USA, UK, Europe and Australia, It will be of value to practising psychiatrists and to trainees, as well as to clinical and neuroscience researchers interested in keeping up with this field or coming into it.\u003c\/p\u003e \u003cp\u003eThe book consists of four sections:   descriptive aspects, biological aspects, physical treatments, and psychological and social aspects.   It reviews the theoretical controversies over symptomatology, classification and aetiology (particularly pertinent as DSM-V is being developed), the relationship of schizophrenia to the other psychoses, the significance of positive and negative symptoms and pre-morbid personality. It describes a variety of approaches to integrating the vast research data about schizophrenia, including neurodevelopmental, genetic, pharmacological, brain imaging and psychological findings. The biological treatment section reviews the comparative efficacy of various drugs, the management of drug-resistant patients and both neurological and metabolic complications. The final section looks at psychological therapies, social outcomes, and the economics of schizophrenia. \u003c\/p\u003e","brand":"Wiley-Blackwell","offers":[{"title":"Default Title","offer_id":47989991604453,"sku":"NP9781405176972","price":267.95,"currency_code":"USD","in_stock":false}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/1842\/7735\/files\/9781405176972.jpg?v=1761786133","url":"https:\/\/k12savings.com\/products\/schizophrenia-isbn-9781405176972","provider":"K12savings","version":"1.0","type":"link"}